Literature DB >> 28820968

Reduced activin receptor-like kinase 1 activity promotes cardiac fibrosis in heart failure.

Kevin J Morine1, Xiaoying Qiao1, Vikram Paruchuri1, Mark J Aronovitz1, Emily E Mackey1, Lyanne Buiten1, Jonathan Levine1, Keshan Ughreja1, Prerna Nepali1, Robert M Blanton1, S Paul Oh2, Richard H Karas1, Navin K Kapur3.   

Abstract

INTRODUCTION: Activin receptor-like kinase 1 (ALK1) mediates signaling via the transforming growth factor beta-1 (TGFβ1), a pro-fibrogenic cytokine. No studies have defined a role for ALK1 in heart failure. HYPOTHESIS: We tested the hypothesis that reduced ALK1 expression promotes maladaptive cardiac remodeling in heart failure. METHODS AND
RESULTS: In patients with advanced heart failure referred for left ventricular (LV) assist device implantation, LV Alk1 mRNA and protein levels were lower than control LV obtained from patients without heart failure. To investigate the role of ALK1 in heart failure, Alk1 haploinsufficient (Alk1+/-) and wild-type (WT) mice were studied 2 weeks after severe transverse aortic constriction (TAC). LV and lung weights were higher in Alk1+/- mice after TAC. Cardiomyocyte area and LV mRNA levels of brain natriuretic peptide and β-myosin heavy chain were increased similarly in Alk1+/- and WT mice after TAC. Alk-1 mice exhibited reduced Smad 1 phosphorylation and signaling compared to WT mice after TAC. Compared to WT, LV fibrosis and Type 1 collagen mRNA and protein levels were higher in Alk1+/- mice. LV fractional shortening was lower in Alk1+/- mice after TAC.
CONCLUSIONS: Reduced expression of ALK1 promotes cardiac fibrosis and impaired LV function in a murine model of heart failure. Further studies examining the role of ALK1 and ALK1 inhibitors on cardiac remodeling are required.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Activin receptor like kinase 1; Cardiac fibrosis; Heart failure; Transforming growth factor beta

Mesh:

Substances:

Year:  2017        PMID: 28820968      PMCID: PMC5863230          DOI: 10.1016/j.carpath.2017.07.004

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  24 in total

1.  Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure.

Authors:  Navin K Kapur; Szuhuei Wilson; Adil A Yunis; Xiaoying Qiao; Emily Mackey; Vikram Paruchuri; Corey Baker; Mark J Aronovitz; S Ananth Karumanchi; Michelle Letarte; David A Kass; Michael E Mendelsohn; Richard H Karas
Journal:  Circulation       Date:  2012-05-16       Impact factor: 29.690

2.  PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.

Authors:  A Necchi; P Giannatempo; L Mariani; E Farè; D Raggi; M Pennati; N Zaffaroni; F Crippa; A Marchianò; N Nicolai; M Maffezzini; E Togliardi; M G Daidone; A M Gianni; R Salvioni; F De Braud
Journal:  Invest New Drugs       Date:  2014-02-26       Impact factor: 3.850

3.  Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.

Authors:  M Simonelli; P Zucali; A Santoro; M B Thomas; F G de Braud; H Borghaei; J Berlin; C S Denlinger; C Noberasco; L Rimassa; T-Y Kim; P A English; A Abbattista; C Gallo Stampino; M Carpentieri; J A Williams
Journal:  Ann Oncol       Date:  2016-06-20       Impact factor: 32.976

4.  Conditional knockout of activin like kinase-1 (ALK-1) leads to heart failure without maladaptive remodeling.

Authors:  Kevin J Morine; Xiaoying Qiao; Vikram Paruchuri; Mark J Aronovitz; Emily E Mackey; Lyanne Buiten; Jonathan Levine; Keshan Ughreja; Prerna Nepali; Robert M Blanton; Richard H Karas; S Paul Oh; Navin K Kapur
Journal:  Heart Vessels       Date:  2017-02-17       Impact factor: 2.037

Review 5.  TGFβ signalling in context.

Authors:  Joan Massagué
Journal:  Nat Rev Mol Cell Biol       Date:  2012-09-20       Impact factor: 94.444

6.  Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis.

Authors:  S P Oh; T Seki; K A Goss; T Imamura; Y Yi; P K Donahoe; L Li; K Miyazono; P ten Dijke; S Kim; E Li
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

7.  Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.

Authors:  Lukas J A C Hawinkels; Amaya Garcia de Vinuesa; Madelon Paauwe; Marianna Kruithof-de Julio; Eliza Wiercinska; Evangelia Pardali; Laura Mezzanotte; Stijn Keereweer; Tanya M Braumuller; Renier C Heijkants; Jos Jonkers; Clemens W Löwik; Marie-José Goumans; Timo L ten Hagen; Peter ten Dijke
Journal:  Clin Cancer Res       Date:  2015-09-15       Impact factor: 12.531

8.  Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.

Authors:  Johanna C Bendell; Michael S Gordon; Herbert I Hurwitz; Suzanne F Jones; David S Mendelson; Gerard C Blobe; Neeraj Agarwal; Carolyn H Condon; Dawn Wilson; Amelia E Pearsall; Yijun Yang; Ty McClure; Kenneth M Attie; Matthew L Sherman; Sunil Sharma
Journal:  Clin Cancer Res       Date:  2013-10-30       Impact factor: 12.531

9.  Biventricular remodeling in murine models of right ventricular pressure overload.

Authors:  Navin K Kapur; Vikram Paruchuri; Mark J Aronovitz; Xiaoying Qiao; Emily E Mackey; Gerard H Daly; Kishan Ughreja; Jonathan Levine; Robert Blanton; Nicholas S Hill; Richard H Karas
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

10.  A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors.

Authors:  Toshihiko Doi; Kyung-Hun Lee; Tae-Min Kim; Atsushi Ohtsu; Tae Yong Kim; Masafumi Ikeda; Kiyotaka Yoh; Corrado Gallo Stampino; Tomoko Hirohashi; Akiyuki Suzuki; Yosuke Fujii; James Andrew Williams; Yung-Jue Bang
Journal:  Cancer Med       Date:  2016-04-14       Impact factor: 4.452

View more
  9 in total

1.  Atrial overexpression of microRNA-27b attenuates angiotensin II-induced atrial fibrosis and fibrillation by targeting ALK5.

Authors:  Yanshan Wang; Heng Cai; Hongmei Li; Zhisheng Gao; Kunqing Song
Journal:  Hum Cell       Date:  2018-04-18       Impact factor: 4.174

2.  Endothelial Activin Receptor-Like Kinase 1 (ALK1) Regulates Myofibroblast Emergence and Peritubular Capillary Stability in the Early Stages of Kidney Fibrosis.

Authors:  Carlos Martínez-Salgado; Fernando Sánchez-Juanes; Francisco J López-Hernández; José M Muñoz-Félix
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

Review 3.  Signaling cascades in the failing heart and emerging therapeutic strategies.

Authors:  Xin He; Tailai Du; Tianxin Long; Xinxue Liao; Yugang Dong; Zhan-Peng Huang
Journal:  Signal Transduct Target Ther       Date:  2022-04-23

4.  Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure.

Authors:  Kevin J Morine; Xiaoying Qiao; Sam York; Peter S Natov; Vikram Paruchuri; Yali Zhang; Mark J Aronovitz; Richard H Karas; Navin K Kapur
Journal:  Circulation       Date:  2018-07-31       Impact factor: 29.690

5.  Exogenous BMP9 promotes lung fibroblast HFL-1 cell activation via ALK1/Smad1/5 signaling in vitro.

Authors:  Yaqun Wang; Xiaonan Sima; Ying Ying; Yonghong Huang
Journal:  Exp Ther Med       Date:  2021-05-04       Impact factor: 2.447

6.  Distinct Phenotypes Induced by Three Degrees of Transverse Aortic Constriction in Mice.

Authors:  Daniel A Richards; Mark J Aronovitz; Timothy D Calamaras; Kelly Tam; Gregory L Martin; Peiwen Liu; Heather K Bowditch; Phyllis Zhang; Gordon S Huggins; Robert M Blanton
Journal:  Sci Rep       Date:  2019-04-10       Impact factor: 4.379

Review 7.  Differential Role of Transforming Growth Factor-beta in an Osteoarthritic or a Healthy Joint.

Authors:  Peter M van der Kraan
Journal:  J Bone Metab       Date:  2018-05-31

8.  Subaortic Membranes in Patients With Hereditary Hemorrhagic Telangiectasia and Liver Vascular Malformations.

Authors:  Agnes S Kim; Katharine J Henderson; Sumeet Pawar; Min Jung Kim; Shahnaz Punjani; Jeffrey S Pollak; John T Fahey; Guadalupe Garcia-Tsao; Lissa Sugeng; Lawrence H Young
Journal:  J Am Heart Assoc       Date:  2020-10-15       Impact factor: 5.501

9.  Alk1 haploinsufficiency causes glomerular dysfunction and microalbuminuria in diabetic mice.

Authors:  Cindy Lora Gil; Nathalie Henley; François A Leblond; Naoufal Akla; Louis-Philippe Laurin; Virginie Royal; Casimiro Gerarduzzi; Vincent Pichette; Bruno Larrivée
Journal:  Sci Rep       Date:  2020-08-04       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.